User:Mr. Ibrahem/Trastuzumab emtansine

Trastuzumab emtansine, sold under the trade name Kadcyla, is a medication used to treat breast cancer. Specifically it is used for HER2 positive which have been treated with other medications. It improved overall survival from 25 months to 31 months. It is given by injection into a vein.

Common side effects include tiredness, nausea, liver problems, bleeding, muscle pain, and constipation. Other side effects may include lung problems, infusion reactions, and neurological problems. Use in pregnancy may harm the baby. It is an antibody-drug conjugate. It consists of the monoclonal antibody trastuzumab that binds to HER2 linked to the cytotoxic agent DM1.

Trastuzumab emtansine was approved for medical use in the United States and Europe in 2013. In the United Kingdom the dose for a 70 kg person costs the NHS about £4,300 every 3 weeks as of 2021. This amount in the United States is about 9,400 USD.